AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,179,059 | +0.6% | 5,606,166 | +3.9% | 0.01% | 0.0% |
| Q2 2023 | $67,768,831 | +18.8% | 5,395,606 | +4.9% | 0.01% | +14.3% |
| Q1 2023 | $57,029,313 | +95407.3% | 5,142,407 | +5.2% | 0.01% | -12.5% |
| Q4 2022 | $59,712 | -99.9% | 4,890,428 | +3.5% | 0.01% | +14.3% |
| Q3 2022 | $49,306,000 | -1.5% | 4,722,886 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $50,040,000 | +17.0% | 4,659,254 | +3.2% | 0.01% | +40.0% |
| Q1 2022 | $42,768,000 | -21.7% | 4,516,251 | -4.5% | 0.01% | -28.6% |
| Q4 2021 | $54,593,000 | +28.4% | 4,726,733 | +6.2% | 0.01% | +16.7% |
| Q3 2021 | $42,505,000 | -5.1% | 4,450,822 | -4.2% | 0.01% | 0.0% |
| Q2 2021 | $44,786,000 | +3.6% | 4,645,931 | +6.2% | 0.01% | -14.3% |
| Q1 2021 | $43,227,000 | -53.9% | 4,375,227 | +7.8% | 0.01% | -56.2% |
| Q4 2020 | $93,724,000 | +72.9% | 4,059,103 | +5.7% | 0.02% | +45.5% |
| Q3 2020 | $54,222,000 | -7.2% | 3,840,091 | -0.9% | 0.01% | -8.3% |
| Q2 2020 | $58,410,000 | +65.9% | 3,873,390 | +1.7% | 0.01% | +33.3% |
| Q1 2020 | $35,202,000 | -48.5% | 3,809,835 | -45.7% | 0.01% | +28.6% |
| Q4 2019 | $68,298,000 | +153.5% | 7,012,142 | +108.7% | 0.01% | +16.7% |
| Q3 2019 | $26,940,000 | -32.0% | 3,359,214 | +5.8% | 0.01% | -40.0% |
| Q2 2019 | $39,642,000 | +7.0% | 3,176,491 | +16.6% | 0.01% | 0.0% |
| Q1 2019 | $37,049,000 | -11.4% | 2,724,207 | -37.6% | 0.01% | +66.7% |
| Q4 2018 | $41,838,000 | +72.8% | 4,367,358 | +118.1% | 0.01% | -14.3% |
| Q3 2018 | $24,213,000 | -19.3% | 2,002,741 | +4.2% | 0.01% | -22.2% |
| Q2 2018 | $30,012,000 | +14.6% | 1,921,442 | +10.3% | 0.01% | 0.0% |
| Q1 2018 | $26,196,000 | +16.2% | 1,741,813 | +11.2% | 0.01% | +12.5% |
| Q4 2017 | $22,538,000 | +1.5% | 1,566,261 | +6.3% | 0.01% | 0.0% |
| Q3 2017 | $22,214,000 | +76.3% | 1,473,089 | +17.8% | 0.01% | +60.0% |
| Q2 2017 | $12,597,000 | +51.4% | 1,251,025 | +7.2% | 0.01% | +66.7% |
| Q1 2017 | $8,323,000 | +50.2% | 1,167,356 | +4.7% | 0.00% | 0.0% |
| Q4 2016 | $5,543,000 | -30.0% | 1,115,353 | +4.3% | 0.00% | -25.0% |
| Q3 2016 | $7,913,000 | +69.2% | 1,069,349 | +24.8% | 0.00% | +33.3% |
| Q2 2016 | $4,677,000 | -34.2% | 856,747 | +1.8% | 0.00% | -25.0% |
| Q1 2016 | $7,110,000 | -9.3% | 841,457 | +4.1% | 0.00% | 0.0% |
| Q4 2015 | $7,837,000 | -25.2% | 808,008 | +7.8% | 0.00% | -33.3% |
| Q3 2015 | $10,484,000 | +5.7% | 749,398 | +6.9% | 0.01% | 0.0% |
| Q2 2015 | $9,922,000 | +123.7% | 701,256 | +72.0% | 0.01% | +100.0% |
| Q1 2015 | $4,436,000 | +34.2% | 407,731 | +2.6% | 0.00% | +50.0% |
| Q4 2014 | $3,306,000 | +126.3% | 397,448 | +61.8% | 0.00% | +100.0% |
| Q3 2014 | $1,461,000 | +218.3% | 245,581 | +78.4% | 0.00% | – |
| Q2 2014 | $459,000 | +38.7% | 137,674 | -14.0% | 0.00% | – |
| Q1 2014 | $331,000 | -9.1% | 160,080 | +3.2% | 0.00% | – |
| Q4 2013 | $364,000 | +3.1% | 155,104 | +2.0% | 0.00% | – |
| Q3 2013 | $353,000 | +2.0% | 152,119 | +2.4% | 0.00% | – |
| Q2 2013 | $346,000 | – | 148,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |